BD 2671910 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 0.75", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

BD 2671910 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 0.75", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

The BD 2671934 PowerLoc PAK Safety Infusion Set is a sterile, single-use port-access solution designed for accessing compatible surgically implanted vascular ports. The set features a 19-gauge non-coring needle with a 0.75-inch length and includes a Y-injection site for secondary access to the infusion pathway.

The PowerLoc system provides a fluid pathway for administering compatible medications and solutions, withdrawing blood specimens, flushing implanted ports, and delivering contrast media through appropriately rated power-injectable ports. The 19-gauge configuration supports higher-flow infusion and imaging applications, while the 0.75-inch needle length is intended for implanted ports positioned relatively close to the skin surface.

The integrated safety mechanism is designed to help reduce accidental needlestick exposure during port deaccessing. As the needle is withdrawn from the implanted port and enters the base, a protective shield moves over the needle point and the needle locks into position. Tactile, audible, and visual confirmation helps clinicians verify safety activation before transportation and disposal.

The PowerLoc design provides a small, lightweight, and low-profile footprint to support dressing application, access-site visibility, and patient comfort. The winged configuration assists with controlled needle placement and stabilization during port access.

The PAK presentation combines essential port-access components within a single organized package to help simplify sterile preparation and promote consistency during port-access procedures. BD 2671934 is supplied five sets per case.

Key Benefits

• 19-gauge non-coring needle supports access to compatible implanted vascular ports.
• 0.75-inch needle length accommodates appropriately positioned superficial ports.
• Power-injectable design supports compatible contrast-enhanced imaging procedures.
• Supports power-injection flow rates up to 5 mL per second when the complete system is properly rated.
• Y-injection site provides secondary access for compatible medication or fluid administration.
• Non-coring needle design helps minimize unnecessary damage to the implanted port septum.
• Integrated safety shield covers the needle point following port deaccessing.
• Needle lockout provides tactile, audible, and visual confirmation of safety activation.
• Small, low-profile footprint supports dressing placement and access-site management.
• Lightweight construction helps reduce unnecessary bulk at the port-access site.
• Winged design supports controlled insertion, stabilization, and site visibility.
• Downward-angled tubing helps support dressing integrity and tubing positioning.
• Compatible with appropriate dual-lumen implanted port applications.
• Power-injection identification supports communication with diagnostic imaging personnel.
• PAK configuration helps organize essential port-access components in one sterile package.
• Five-per-case packaging supports controlled clinical inventory management.

Compatibility and Applications

The BD 2671934 PowerLoc PAK Safety Infusion Set is intended for use with compatible surgically implanted vascular access ports designed to accept non-coring port-access needles.

Potential clinical applications include chemotherapy administration, antibiotic therapy, hydration, parenteral nutrition, blood product administration, long-term infusion therapy, blood specimen collection, implanted port flushing, and contrast-media delivery during compatible diagnostic imaging procedures.

The 19-gauge needle may be selected when the prescribed therapy requires higher flow capability or when the implanted port and complete access system are suitable for a larger-gauge port-access device. Selection should consider medication viscosity, required flow rate, infusion-pump settings, power-injection requirements, and the implanted port manufacturers instructions.

The 0.75-inch needle length is generally appropriate for ports positioned close to the skin surface. Clinicians should assess the depth of the port septum before product selection. A needle that is too short may not enter the septum completely, while an unnecessarily long needle may affect stability, securement, and dressing placement.

The integrated Y-injection site provides a secondary access point within the tubing. It may support compatible intermittent medication administration, flushing, or connection of an additional infusion pathway when permitted by the clinical procedure and institutional protocol.

When the set is used for power injection, the implanted port, access needle, tubing, connectors, Y-site, extension components, and all other devices within the fluid pathway must be specifically rated for power injection. The pressure and flow rate must not exceed the lowest-rated component within the complete system.

Compatibility should be confirmed with the exact implanted port model, septum design, port depth, prescribed therapy, infusion pump, power injector, needleless connector, dressing materials, and institutional vascular-access procedures.

Usage Guidelines

The BD 2671934 should be used only by healthcare professionals who are trained and authorized to access implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and the implanted port manufacturers directions should be followed throughout the procedure.

• Confirm the patients identity, prescribed therapy, implanted port type, and power-injection status.
• Assess the location and depth of the implanted port before selecting the 0.75-inch needle.
• Verify that the 19-gauge configuration is appropriate for the intended infusion or imaging procedure.
• Confirm that a Y-injection site is suitable for the planned clinical workflow.
• Inspect the sterile package for punctures, moisture, damage, contamination, or compromised integrity.
• Prepare the port-access site using the antiseptic procedure required by institutional policy.
• Prime the primary tubing and Y-injection pathway completely with an approved solution.
• Remove air from the complete fluid pathway before accessing the implanted port.
• Stabilize the port and insert the non-coring needle perpendicular to the septum using an approved technique.
• Advance the needle carefully until appropriate contact with the base of the port reservoir is achieved.
• Verify correct needle placement according to institutional policy, including aspiration for blood return when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and facility protocol.
• Position the wings and tubing to reduce pressure, pulling, twisting, and dressing disruption.
• Secure the access set and apply an approved sterile dressing.
• Disinfect the Y-injection site before every connection or access according to facility protocol.
• Maintain aseptic non-touch technique when accessing the Y-site.
• Monitor the site for pain, swelling, redness, leakage, displacement, or other complications.
• Confirm power-injection eligibility before connecting the set to a power injector.
• Do not exceed 5 mL per second or the lower operating limit of any connected component.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the port while withdrawing the needle and activating the safety mechanism.
• Confirm safety activation through tactile feel, the audible click, and visual inspection.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the port-access system if resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, or another abnormality develops at the access site.

Certifications and Safety Standards

The BD 2671934 PowerLoc PAK Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The product is supplied in a sterile, single-use configuration. Maintaining package integrity and using appropriate aseptic technique are essential for preserving product sterility before use.

The safety mechanism is designed to cover and lock the needle point following removal from the implanted port. Tactile, audible, and visual confirmation supports verification of needle lockout before handling and disposal.

The safety feature does not replace appropriate clinician training, careful sharps handling, personal protective equipment, exposure-control procedures, or immediate disposal in an approved sharps container.

The PAK configuration supports standardized port-access preparation by combining essential procedural components within one organized package. Healthcare facilities should incorporate the set into policies addressing hand hygiene, sterile-field preparation, skin antisepsis, port access, connection management, dressing application, deaccessing, and sharps disposal.

Healthcare organizations should review current manufacturer documentation for applicable FDA clearance, UDI information, sterilization method, material composition, natural rubber latex status, DEHP information, shelf life, maximum pressure, flow-rate limits, and other technical or regulatory requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety features, the BD PowerLoc includes a passive mechanism that covers and locks the needle point during deaccessing. This can help reduce accidental needlestick exposure between removal and final disposal.

Compared with infusion sets that do not include a Y-injection site, BD 2671934 provides a secondary access point within the tubing. This may support compatible intermittent medication administration or additional fluid connections without disconnecting the primary pathway.

Compared with non-power-injectable port-access sets, the PowerLoc system supports compatible power-injection procedures when used with an approved power-injectable port and within the specified pressure and flow limits.

Compared with 20-gauge or 22-gauge PowerLoc configurations, the 19-gauge needle provides a larger internal pathway that may support higher-flow or more viscous fluid applications. The larger gauge should be selected only when appropriate for the implanted port and prescribed procedure.

Compared with 1-inch and 1.5-inch access needles, the 0.75-inch configuration provides a lower profile for ports positioned closer to the skin surface. Correct needle-length selection can help support secure septum access and effective dressing placement.

Compared with loose individual port-access supplies, the PAK presentation organizes essential components within one sterile package. This may help simplify supply preparation, reduce the need to gather separate products, and support consistency across clinicians and clinical settings.

Alternative safety infusion sets may differ in gauge, needle length, power-injection capability, Y-site design, tubing configuration, safety activation method, wing profile, included kit components, and package quantity. BD 2671934 combines a 19-gauge, 0.75-inch non-coring needle with a Y-injection site, integrated safety mechanism, and organized PAK presentation.

Typical User Profile and Application Scenarios

The BD 2671934 PowerLoc PAK Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified clinical personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, emergency departments, specialty practices, and other healthcare facilities where implanted ports are routinely accessed.

The product may be selected for patients whose implanted port can be accessed appropriately with a 0.75-inch needle and whose prescribed therapy or diagnostic procedure is compatible with a 19-gauge access device.

Typical application scenarios include chemotherapy administration, antibiotic infusion, hydration, parenteral nutrition, blood product delivery, blood specimen collection, routine port maintenance, and power injection of contrast media during compatible imaging procedures.

The Y-injection site is particularly useful in workflows that require secondary access for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway.

Best Practices for Use and Maintenance

The BD 2671934 is a sterile, single-use medical device and does not require maintenance as reusable equipment. Best practices focus on proper storage, product selection, sterile preparation, port-access technique, Y-site management, site monitoring, safety activation, and disposal.

• Store unopened sets under the environmental conditions specified by the manufacturer.
• Protect packages from moisture, excessive heat, freezing, crushing, punctures, and contamination.
• Rotate inventory according to expiration dates and facility stock-control procedures.
• Verify the BD 2671934 catalog number before opening the package.
• Confirm the 19-gauge size, 0.75-inch length, and presence of the Y-injection site.
• Assess the patients tissue depth and implanted port position before selecting the needle length.
• Confirm that the required therapy and flow rate are appropriate for a 19-gauge device.
• Use strict aseptic technique during preparation, priming, insertion, connection, and dressing application.
• Prime all intended fluid pathways completely before connecting the set to the implanted port.
• Stabilize the port during both needle insertion and removal.
• Position the tubing without creating pulling or pressure at the access site.
• Scrub and disinfect the Y-injection site before each access according to institutional policy.
• Use a new sterile access device for every Y-site connection when required.
• Keep unused access points capped and protected from contamination.
• Monitor the port site and tubing connections throughout therapy.
• Verify the power-injectable status of the complete system before a powered procedure.
• Never exceed the lowest pressure or flow-rate limit of any connected component.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Do not reuse, clean, resterilize, or reprocess the single-use device.
• Verify complete safety activation immediately after needle withdrawal.
• Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 2671934 PowerLoc PAK Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

Before use, verify the product identity, 19-gauge size, 0.75-inch needle length, Y-injection site configuration, sterile package integrity, expiration date, and compatibility with the implanted vascular port. Do not use a device that is expired, damaged, contaminated, or supplied in compromised packaging.

The set should not be used for power injection unless the implanted port and every connected component are specifically rated for power injection. The permitted pressure, flow rate, contrast-media viscosity, and other operating conditions must be confirmed before beginning the procedure.

Compatible 19-gauge PowerLoc configurations support power-injection flow rates up to 5 mL per second when used under manufacturer-specified conditions. The lowest-rated component within the complete system determines the maximum allowable operating limit.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may cause infiltration, extravasation, tissue injury, leakage, implanted port damage, interrupted therapy, or other complications.

The Y-injection site should be accessed only with compatible devices and using appropriate disinfection and aseptic technique. Unnecessary manipulation or inadequate disinfection may increase the risk of contamination, connection failure, or bloodstream infection.

The safety mechanism must be activated according to current manufacturer instructions. The used device remains a contaminated sharp even after the needle point is covered and must be discarded immediately in an approved sharps container.

The product is supplied five sets per case. The CIA Medical listing identifies this configuration as temperature sensitive, non-returnable, restricted to continental United States distribution, and supplied as a special-order item. Purchasing personnel should confirm current availability, shipping eligibility, storage requirements, and return conditions before ordering.

How to Order

Select the BD 2671934 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 19G x 0.75" and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.